Cell-surface membrane proteins provide entry points for therapeutic interventions. 

 

ZnT8, a zinc-specific transporter, is a dynamic cell-surface marker for beta cells. 

​

ZnT8 in the human body is exclusively localized in the pancreatic islet.

​

We have developed a ZnT8-targted drug delivery platform for pancreatic islets.

​

We have established preclinical efficacy and safety of an islet-targeted immunotherapy for type-1 diabetes. 

​

We aim to develop a suite of diabetes-modifying therapeutics that can be administered monthly at home, replacing frequent insulin injections and blood glucose monitoring for patients with insulin-dependent diabetes.

​